Your browser doesn't support javascript.
loading
Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC.
Song, Zhengbo; Lian, Shifeng; Mak, Silvia; Chow, Maggie Zi-Ying; Xu, Chunwei; Wang, Wenxian; Keung, Hoi Yee; Lu, Chenyu; Kebede, Firaol Tamiru; Gao, Yanqiu; Cheuk, Wah; Cho, William Chi Shing; Yang, Mengsu; Zheng, Zongli.
Afiliación
  • Song Z; Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, People's Republic of China.
  • Lian S; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Mak S; Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Sha Tin, Hong Kong Special Administrative Region of the People's Republic of China.
  • Chow MZ; Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Sha Tin, Hong Kong Special Administrative Region of the People's Republic of China.
  • Xu C; Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China.
  • Wang W; Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, People's Republic of China.
  • Keung HY; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, People's Republic of China.
  • Lu C; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong Special Administrative Region of the People's Republic of China; Biotechnology and Health Centre, City University of Hong Kong Shenzhen Research Institute, Shenzhen, People's Republic of China.
  • Kebede FT; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong Special Administrative Region of the People's Republic of China.
  • Gao Y; Helitec Limited, Shenzhen, People's Republic of China.
  • Cheuk W; Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong Special Administrative Region of the People's Republic of China.
  • Cho WCS; Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong Special Administrative Region of the People's Republic of China.
  • Yang M; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong Special Administrative Region of the People's Republic of China; Biotechnology and Health Centre, City University of Hong Kong Shenzhen Research Institute, Shenzhen, People's Republic of China.
  • Zheng Z; Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Sha Tin, Hong Kong Special Administrative Region of the People's Republic of China; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong Special Administrative Region of the People's Republic of China;
J Thorac Oncol ; 17(2): 264-276, 2022 02.
Article en En | MEDLINE | ID: mdl-34626839
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Crizotinib / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Crizotinib / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2022 Tipo del documento: Article